Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Open access
·2001·The Lancet

Abstract

Background Blood pressure is a determinant of the risk of stroke among both hypertensive and non-hypertensive individuals with cerebrovascular disease. However, there is uncertainty about the efficacy and safety of blood-pressure-lowering treatments for many such patients. The perindopril protection against recurrent stroke study (PROGRESS) was designed to determine the effects of a blood-pressure-lowering regimen in hypertensive and non-hypertensive patients with a history of stroke or transient ischaemic attack.Methods 6105 individuals from 172 centres in Asia, Australasia, and Europe were randomly assigned active treatment (n=3051) or placebo (n=3054). Active treatment comprised a flexible regimen based on the angiotensin- converting-enzyme inhibitor perindopril (4 mg daily), with the addition of the diuretic indapamide at the discretion of treating physicians. The primary outcome was total stroke (fatal or non-fatal). Analysis was by intention to treat.Findings Over 4 years of follow up, active treatment reduced blood pressure by 9/4 mm Hg. 307 (10%) individuals assigned active treatment suffered a stroke, compared with 420 (14%) assigned placebo (relative risk reduction 28% [95% CI 17-38], p<0.0001). Active treatment also reduced the risk of total major vascular events (26% [16-34]). There were similar reductions in the risk of stroke in hypertensive and non-hypertensive subgroups (all p<0.01). Combination therapy with perindopril plus indapamide reduced blood pressure by 12/5 mm Hg and stroke risk by 43% (30-54). Single-drug therapy reduced blood pressure by 5/3 mm Hg and produced no discernable reduction in the risk of stroke.Interpretation This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack. Combination therapy with perindopril and indapamide produced larger blood pressure reductions and larger risk reductions than did single drug therapy with perindopril alone. Treatment with these two agents should now be considered routinely for patients with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(01)06178-5

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 4

  1. Rodgers, 1997, The effects of blood pressure lowering in cerebrovascular disease, Neurol Rev Int, 2, 12
  2. Bosch, 2000, Impact of ramipril and vitamin E on cerebrovascular events in the HOPE (Heart Outcomes Prevention Evaluation) trial, J Am Coll Cardiol, 35, 324A
  3. 1999, PROGRESS (Perindopril Protection Against Recurrent Stroke Study): characteristics of the study population at baseline, J Hypertens, 17, 1647
  4. 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastin Survival Study (4S), Lancet, 344, 1383

Cited by

See all 3,178

Metadata

Venue
The Lancet
Publisher
Elsevier BV
Published
2001-09
Volume
358
Issue
9287
Pages
1033-1041
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W1592471891
Cited by
3,178
References
29
Citations by year
2026: 39 · 2025: 55 · 2024: 53 · 2023: 57 · 2022: 63 · 2021: 65 · 2020: 58 · 2019: 89 · 2018: 97 · 2017: 126 · 2016: 104 · 2015: 86 · 2014: 116 · 2013: 112 · 2012: 133
FWCI
142.30
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
  • ResearchSpace (University of Auckland) (submittedVersion)
Funders
  • Servier
  • National Health and Medical Research Council
  • National Medical Research Council
  • Health Research Council of New Zealand
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords
perindopril, indapamide, blood pressure reduction, stroke prevention, transient ischemic attack, stroke recurrence, ACE inhibitors, diuretics, combination therapy, hypertension, non-hypertensive patients, major vascular events
MeSH terms
Aged, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Diuretics, Drug Therapy, Combination, Female, Humans, Hypertension, Indapamide, Male, Middle Aged, Stroke, Perindopril

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. https://app.cochat.ai/papers/10.1016/s0140-6736(01)06178-5
The paper
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. (2001). The Lancet. https://doi.org/10.1016/s0140-6736(01)06178-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.